A Multicenter Study Evaluating the Discontinuation of Eculizumab Therapy in Children with Atypical Hemolytic Uremic Syndrome

Background: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening thrombotic microangiopathy (TMA), which has been treated successfully with eculizumab. The optimal duration of eculizumab in treating patients with aHUS remains poorly defined. Methods: We conducted a multicenter retro...

Descripción completa

Detalles Bibliográficos
Autores principales: AlZabali, Saeed, AlBatati, Sawsan, Rahim, Khawla, Faqeehi, Hassan, Osman, Abubaker, Bamhraz, Abdulaziz, Saleh, Mohammed A., Kari, Jameela A., Aloufi, Majed, Eid, Loai, Nasser, Haydar, Imam, Abubakr, AlHammadi, Entesar, Alkandari, Omar, Al Riyami, Mohammed, Sethi, Sidharth, Licht, Christoph, Alhasan, Khalid A., AlAnazi, Abdulkarim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688604/
https://www.ncbi.nlm.nih.gov/pubmed/36421183
http://dx.doi.org/10.3390/children9111734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688604/
https://www.ncbi.nlm.nih.gov/pubmed/36421183
http://dx.doi.org/10.3390/children9111734

Ejemplares similares